Blog
RSS FeedPosted by Michael Wonder on 22 Sep 2021
NICE terminates yet another appraisal of a medicine for multiple myeloma
22 September 2021 - This is the eleventh terminated appraisal of a medicine for multiple myeloma. London, we have a ...
Posted by Michael Wonder on 21 Sep 2021
NHS patients gain access to COVID-19 treatment Ronapreve
21 September 2021 - The UK has secured supply of Ronapreve, a new COVID-19 therapeutic developed by Regeneron and Roche ...
Posted by Michael Wonder on 17 Sep 2021
Keytruda made available on the NHS for certain oesophageal cancer patients
17 September 2021 - NICE has recommended MSD’s Keytruda (pembrolizumab) combined with chemotherapy for the first-line treatment of certain oesophageal ...
Posted by Michael Wonder on 16 Sep 2021
BioCryst’s HAE med Orladeyo wins NICE nod
16 September 2021 - BioCryst’s Orladeyo (berotralstat) has received a positive recommendation from NICE for preventing recurrent attacks of hereditary ...
Posted by Michael Wonder on 15 Sep 2021
NICE backs Opdivo for head and neck cancer
15 September 2021 - NICE has recommended Bristol Myers Squibb’s (BMS) immunotherapy Opdivo (nivolumab) for routine use on the NHS ...
Posted by Michael Wonder on 12 Sep 2021
NHS lung cancer patients in England get early access to ‘breakthrough’ cancer drug
10 September 2021 - The MHRA has approved a first-of-its-kind cancer drug – capable of targeting a gene mutation that ...
Posted by Michael Wonder on 09 Sep 2021
Professor Gillian Leng to retire from NICE
9 September 2021 - Professor Leng has spent more than 20 years working at NICE. ...
Posted by Michael Wonder on 09 Sep 2021
NICE recommends treatment for people with juvenile idiopathic arthritis
9 September 2021 - NICE has today published final draft guidance which recommends tofacitinib (Xeljanz; Pfizer) as an option for treating ...
Posted by Michael Wonder on 08 Sep 2021
Nivolumab scores a rare 'no' from NICE
8 September 2021 - Nivolumab scores only its second final rejection to date from NICE. ...
Posted by Michael Wonder on 08 Sep 2021
NICE draft guidance recommends apalutamide for treating prostate cancer
8 September 2021 - NICE has today published final draft guidance which now recommends apalutamide (Erleada; Janssen) plus androgen deprivation therapy ...
Posted by Michael Wonder on 04 Sep 2021
NICE recommends Novartis’ Cosentyx for children with severe psoriasis
3 September 2021 - NICE has recommended Novartis’ interleukin-17A inhibitor Cosentyx (secukinumab) for the treatment of children and young people ...
Posted by Michael Wonder on 01 Sep 2021
NICE approves ground-breaking cholesterol lowering drug inclisiran
1 September 2021 - NICE has today issued draft final guidance recommending the novel anti-cholesterol drug inclisiran (Leqvio and made by ...
Posted by Michael Wonder on 01 Sep 2021
World first agreement between Novartis and the NHS enables broad and rapid access to first-in-class cholesterol-lowering medicine Leqvio (inclisiran)
1 September 2021 - Agreement follows positive NICE recommendation and commits to deliver Leqvio (inclisiran) access via a population health management ...
Posted by Michael Wonder on 27 Aug 2021
NICE ‘no’ for Janssen’s Darzalex combo
27 August 2021 - NICE has published draft guidance stating that it does not recommend Janssen’s Darzalex (daratumumab) plus bortezomib, ...
Posted by Michael Wonder on 25 Aug 2021
NICE publishes appraisal guidance on new medicine for patients with biliary tract cancer
25 August 2021 - Pemigatinib (Pemaryze, Incyte) has a conditional marketing authorisation for the treatment of adults with locally advanced or ...